StockpollyBeta
Get App
Popularity #3,527
RNAC · NASDAQ · Biotechnology

Cartesian Therapeutics (RNAC)

Develops outpatient mRNA CAR-T candidates for autoimmune diseases, led by Descartes-08.

$7.80
vs last close−0.29 (−3.53%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue786330−1100100
Cost of revenue13000000013000
Gross profit−686330−110−12100
7451920182623229232729
Research & development132210131111151514151920
7229777878879
Selling & marketing100000001000
General & administrative6229777877879
Other expenses−130000800−13000
Operating income−13−36−1314−18−27−22−22−21−22−26−29
4−160−430−717438−15−80−1345
Interest income011137222111
Interest expense100000000001
Other non-operating income01604307−17−4−38158013−46
Income before tax−9−197−5714−24−10−1816−36−102−3916
Income tax expense0−190000000−900
Net income from continuing operations−9−178−5714−24−10−1816−36−93−3916
Net income−9−178−5714−24−10−1816−36−93−3914
EPS, basic−$1.74−$41.56−$10.50$0.58−$1.13−$0.07−$0.68$0.61−$1.38−$3.56−$1.46$0.47
EPS, diluted−$1.74−$41.56−$10.50$0.54−$1.13−$0.07−$0.68$0.60−$1.38−$3.46−$1.46$0.46
Weighted average shares, basic555172126262626262729
Weighted average shares, diluted555182126262626262730
EBITDA−13−196−5714−24−9−1716−35−101−3917
Depreciation & amortization000000111111
EBIT−13−197−5714−24−10−1816−36−102−3917